Literature DB >> 19798025

Therapy: rituximab and PML risk-informed decisions needed!

Leonard H Calabrese, Eamonn S Molloy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19798025     DOI： 10.1038/nrrheum.2009.193

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

Review 1.  Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.

Authors:  Leonard H Calabrese; Eamonn S Molloy; DeRen Huang; Richard M Ransohoff
Journal:  Arthritis Rheum       Date:  2007-07

2.  Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.

Authors:  R M Fleischmann
Journal:  Arthritis Rheum       Date:  2009-11

3.  Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.

Authors:  Eamonn S Molloy; Leonard H Calabrese
Journal:  Arthritis Rheum       Date:  2009-12

4.  Malignancy and biologic therapy in rheumatoid arthritis.

Authors:  Johan Askling; Tim Bongartz
Journal:  Curr Opin Rheumatol       Date:  2008-05       Impact factor: 5.006

Review 5.  Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?

Authors:  Eamonn S Molloy; Leonard H Calabrese
Journal:  Autoimmun Rev       Date:  2008-12       Impact factor: 9.754

6.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Authors:  Kenneth R Carson; Andrew M Evens; Elizabeth A Richey; Thomas M Habermann; Daniele Focosi; John F Seymour; Jacob Laubach; Susie D Bawn; Leo I Gordon; Jane N Winter; Richard R Furman; Julie M Vose; Andrew D Zelenetz; Ronac Mamtani; Dennis W Raisch; Gary W Dorshimer; Steven T Rosen; Kenji Muro; Numa R Gottardi-Littell; Robert L Talley; Oliver Sartor; David Green; Eugene O Major; Charles L Bennett
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

7.  Predictors of infection in rheumatoid arthritis.

Authors:  Michele F Doran; Cynthia S Crowson; Gregory R Pond; W Michael O'Fallon; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2002-09

8.  Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.

Authors:  Philip J Mease; Dennis A Revicki; Jacek Szechinski; Maria Greenwald; Alan Kivitz; Leonor Barile-Fabris; Jatinderpal Kalsi; Jennifer Eames; Marjatta Leirisalo-Repo
Journal:  J Rheumatol       Date:  2007-11-15       Impact factor: 4.666

Review 9.  Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.

Authors:  Andrea Rubbert-Roth; Axel Finckh
Journal:  Arthritis Res Ther       Date:  2009-04-06       Impact factor: 5.156
  9 in total
  9 in total

Review 1.  Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.

Authors:  Jeremy M Clain; Rodrigo Cartin-Ceba; Fernando C Fervenza; Ulrich Specks
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

Review 2.  Cerebral vasculitis in adults: what are the steps in order to establish the diagnosis? Red flags and pitfalls.

Authors:  P Berlit; M Kraemer
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 3.  Targeting B cells with biologics in systemic lupus erythematosus.

Authors:  Antonio La Cava
Journal:  Expert Opin Biol Ther       Date:  2010-10-04       Impact factor: 4.388

Review 4.  Microscopic polyangiitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Rheum Dis Clin North Am       Date:  2010-06-11       Impact factor: 2.670

Review 5.  Treatment of proliferative lupus nephritis: a slowly changing landscape.

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Nat Rev Nephrol       Date:  2010-12-21       Impact factor: 28.314

Review 6.  Antibody Based Therapies in Acute Leukemia.

Authors:  Nirali N Shah
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

7.  Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

Authors:  Fernando C Fervenza; Roshini S Abraham; Stephen B Erickson; Maria Valentina Irazabal; Alfonso Eirin; Ulrich Specks; Patrick H Nachman; Eric J Bergstralh; Nelson Leung; Fernando G Cosio; Marie C Hogan; John J Dillon; LaTonya J Hickson; Xujian Li; Daniel C Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-12       Impact factor: 8.237

8.  Rituximab therapy combined with methotrexate for severe necrotizing scleritis in a case of granulomatosis with polyangiitis.

Authors:  Somasheila I Murthy; Sahil Shah; Bhupesh Bagga; Rajkiran Dudam
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

9.  Progressive outer retinal necrosis after rituximab and cyclophosphamide therapy.

Authors:  Mohit Dogra; Priya Bajgai; Ashok Kumar; Aman Sharma
Journal:  Indian J Ophthalmol       Date:  2018-04       Impact factor: 1.848
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.